1
|
Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IY, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YV, Trushnikova TN, Khabirov FA, Chefranova JY, Shchur SG, Dudin VA, Pokhabov DV, Artemeva AV, Eremeeva AV, Linkova YN, Zinkina-Orikhan AV. [Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS]. Zh Nevrol Psikhiatr Im S S Korsakova 2024; 124:86-96. [PMID: 38676683 DOI: 10.17116/jnevro202412404186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2024]
Abstract
OBJECTIVE To evaluate the efficacy and safety of the anti-CD20 monoclonal antibody divozilimab (DIV) used as an intravenous infusion at a dose of 500 mg every 24 weeks during 100 weeks for the treatment of patients with multiple sclerosis (MS), including relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS (SPMS) with relapses. MATERIAL AND METHODS The multicenter, randomized, double-blind and double-masked phase III clinical trial (CT) BCD-132-4/MIRANTIBUS (NCT05385744) included 338 adult patients with MS distributed in a 1:1 ratio into two groups: DIV 500 mg and teriflunomide (TRF) 14 mg. After screening, subjects were included in the main CT period, which consisted of two cycles of therapy over 48 weeks, then entered an additional period from weeks 49 to 100, which included three cycles of therapy. The efficacy was assessed based on the results of brain MRI and registration of data on relapses. RESULTS 308 subjects completed 5 therapy cycles according to the study protocol. An analysis of the effectiveness of DIV therapy over 2 years showed a persistent suppression of MRI and clinical activity of the disease in comparison with TRF, which was confirmed by all the studied MRI indicators (including CUA; total number of gadolinium-enhancing (GdE) lesions on T1-weighted scans ; number of new or enlarged lesions on T2-weighted scans; lesions volume change on T2-weighted scans; change in the volume of hypointense lesions on T1-weighted scans). The use of DIV was associated with a statistically significant decrease in ARR compared to TRF (p=0.0001). The ARR in the DIV group was 0.057, in the TRF group - 0.164 with 95% confidential interval for the frequency ratio [0.202; 0.593]. The incidence of GdE lesions on T1-weighted scans in the DIV group was significantly lower than in the TRF group. The average number of such lesions was 0.0±0.08 and 1.0±4.46 in the DIV and TRF groups, respectively (p<0.0001). Progression of EDSS was detected in 18 (10.7%) and 36 (21.3%) patients in the DIV and TRF groups, respectively (p=0.0075). The proportion of patients with relapses was 11.2% (n=19) in the DIV group and 23.1% (n=39) in the TRF group (p=0.0039). In the subpopulation of patients with SPMS, no cases of increase in EDSS were detected, and not a single case of exacerbation was recorded over 2 years of using DIV. Also, DIV has shown a favorable safety profile. Among the adverse reactions (AR), infusion reactions and laboratory abnormalities, such as a decrease in the number of leukocytes, neutrophils, and lymphocytes, were most often recorded. Identified AR were expected, had mild to moderate severity, and resolved without any negative consequences. CONCLUSION The results of the BCD-132-4/MIRANTIBUS CT indicate a high sustained efficacy and safety of long-term use of DIV in comparison with TRF during 2 years of therapy.
Collapse
Affiliation(s)
- A N Boyko
- Pirogov Russian National Research Medical University, Moscow, Russia
- Federal Center of Brain and Neurotechnologies, Moscow, Russia
| | | | | | | | - I V Greshnova
- Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Russia
| | - L G Zaslavsky
- Leningrad Regional Clinical Hospital, St. Petersburg, Russia
| | - S V Kotov
- Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia
| | - N A Malkova
- State Novosibirsk Regional Clinical Hospital, Novosibirsk, Russia
| | - G N Mishin
- Pyatigorsk City Clinical Hospital No. 2, Pyatigorsk, Russia
| | - E V Parshina
- Semashko Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod, Russia
| | | | - L N Prakhova
- N. Bechtereva Institute of the Human Brain, St. Petersburg, Russia
| | | | | | - N A Totolyan
- Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia
| | | | | | - F A Khabirov
- Republican Clinical Nerological Center, Kazan, Russia
| | - J Yu Chefranova
- Belgorod Regional Clinical Hospital of St. Joasaph, Belgorod, Russia
| | - S G Shchur
- Municipal Filatov Clinical Hospital No. 15, Moscow, Russia
| | - V A Dudin
- Center for Cardiology and Neurology, Kirov, Russia
| | - D V Pokhabov
- Federal Siberian Scientific and Clinical Center, Krasnoyarsk, Russia
| | | | | | | | | |
Collapse
|
2
|
Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IY, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YV, Trushnikova TN, Khabirov FA, Shchur SG, Artemyeva AV, Bolsun DD, Zinkina-Orikhan AV, Linkova YN. [Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2]. Zh Nevrol Psikhiatr Im S S Korsakova 2023; 123:37-47. [PMID: 37084363 DOI: 10.17116/jnevro202312304137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/23/2023]
Abstract
OBJECTIVE To find the optimal therapeutic dose of the anti-B cell mAb divozilimab (DIV) based on the efficacy and safety data of intravenous administration at a dose of 125 mg or 500 mg in patients with relapsing remitting multiple sclerosis (RRMS) compared to placebo (PBO) and teriflunomide (TRF). To study the efficacy and safety of DIV within 24 weeks of treatment. MATERIAL AND METHODS A multicenter, randomized, double-blind and double-masked, placebo-controlled phase 2 clinical trial (CT) BCD-132-2 involved 271 adult patients with RRMS from 25 centres In Russia. Patients were randomly assigned (2:2:2:1) into 4 groups: TRF, DIV 125 mg, DIV 500 mg and PBO. After screening patients entered to the main period, which consisted of one cycle of therapy for 24 weeks. The primary endpoint was the total number of gadolinium-enhancing T1 lesions (Gd+) observed on brain MRI scans after 24 weeks (per scan - involves estimating the mean value of the score from all the MRI assessments performed for each participant in the study). RESULTS 263 patients completed 24 weeks of treatment. Most of the patients in the DIV groups had no lesions on T1-weighted MRI after 24 weeks of treatment (94.44% on 125 mg and 93.06% on 500 mg). In the TRF and PBO groups the values were significantly lower: 68.06% and 56.36% respectively (both p<0.05). The proportions of relapse-free patients in the DIV groups were 93.06% and 97.22% (125 mg and 500 mg, respectively). As expected, DIV reduced the CD19+ B-cells. However, the repopulation rate of CD19+ B-cells in the 125 mg group was more pronounced (mainly due to the recovering pool of CD27-naive B-cells) compared to the 500 mg group. DIV showed a favorable safety profile at both doses. CONCLUSION Thus, the assessment of 24 weeks treatment demonstrated that DIV is a highly effective, safe and convenient option for the treatment of RRMS patients, both naive and previously treated with disease modifying therapy. A dose of 500 mg is recommended for further efficacy and safety evaluation during phase 3 CT.
Collapse
Affiliation(s)
- A N Boyko
- Pirogov Russian National Research Medical University, Moscow, Russia
- Federal Center of Brain and Neurotechnologies, Moscow, Russia
| | | | - I G Lukashevich
- Orden of the Red Banner of Labor City Clinical Hospital No. 1, Chelyabinsk, Russia
| | | | - I V Greshnova
- Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Russia
| | - L G Zaslavsky
- Leningrad Regional Clinical Hospital, St. Petersburg, Russia
| | - S V Kotov
- Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia
| | - N A Malkova
- State Novosibirsk Regional Clinical Hospital, Novosibirsk, Russia
| | - G N Mishin
- Pyatigorsk City Clinical Hospital No. 2, Pyatigorsk, Russia
| | - E V Parshina
- Semashko Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod, Russia
| | | | - L N Prakhova
- N. Bechtereva Institute of the Human Brain, St. Petersburg, Russia
| | | | | | - N A Totolyan
- Academician I.P. Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia
| | | | | | - F A Khabirov
- Republican Clinical Nerological Center, Kazan, Russia
| | - S G Shchur
- Municipal Filatov Clinical Hospital No. 15, Moscow, Russia
| | | | | | | | | |
Collapse
|
3
|
Tkacheva ON, Mkhitaryan EA, Kolykhalov IV, Belova AN, Kolokolov OV, Zaslavsky LG, Khasanova NM, Akhmadeeva LR, Bogdanov EI. [Treatment of cognitive, behavioral and mental disorders in patients with vascular dementia: results of a multicenter, randomized, double-blind, placebo-controlled clinical trial]. Zh Nevrol Psikhiatr Im S S Korsakova 2023; 123:41-49. [PMID: 37490664 DOI: 10.17116/jnevro202312307141] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/27/2023]
Abstract
OBJECTIVE Evaluation of the efficacy and safety of Prospect in the treatment of cognitive, behavioral and mental disorders in patients with vascular dementia (VSD). MATERIAL AND METHODS In a double-blind, placebo-controlled, parallel-group randomised clinical trial, 406 patients aged 60-85 years old with a diagnosis of mild/moderate vascular dementia (10-24 on the Mini-Mental State Examination (MMSE)) and without signs of depression (Cornell Scale for Depression in Dementia (CSDD) scores ≤10) were included. At Visit 1, complaints and medical history were collected, vital signs were recorded, cognitive impairment was assessed using MMSE and MoCA, NPI-C and CSDD were completed, and an MRI brain scan was performed. Patients were randomised into two groups: patients in group 1 received Prospekta in a dosage of 2 tablets two times a day for 24 weeks, and patients in group 2 received Placebo according to the study drug regimen. RESULTS Patients in both groups had no differences in demographic and baseline clinical characteristics. Administration of Prospekta for 24 weeks reduced cognitive impairment in patients with vascular dementia compared to the placebo group. The mean MoCA score increased from 17.0±3.6 [17.1±3.6] to 20.5±4.7 [20.4±4.7] in patients treated with Prospekta, whereas it increased from 17.3±3.7 [17.3±3.8] to 19.2±4.9 [19.2±5.0] in the Placebo group. Treatment with the medication also reduced the severity of neuropsychiatric symptoms as measured by the NPI-C scale. The mean score on this scale decreased from 57.0±26.7 [56.7±25.4] to 39.8±23.6 [39.8±23.5] in the Prospekta group and from 55.5±25.5 [55.3±24.4] to 42.8±27.6 [42.3±25.3] in the Placebo group. The difference in mean MoCA and NPI-C scores between the Prospekta and Placebo groups was statistically significant. CONCLUSION Prospekta is an effective and safe drug for treating cognitive, behavioural and mental disturbances in patients with vascular dementia.
Collapse
Affiliation(s)
- O N Tkacheva
- Pirogov Russian National Research Medical University, Moscow, Russia
- Russian Clinical and Research Center of Gerontology of the Pirogov Russian National Research Medical University, Moscow, Russia
| | - E A Mkhitaryan
- Pirogov Russian National Research Medical University, Moscow, Russia
- Russian Clinical and Research Center of Gerontology of the Pirogov Russian National Research Medical University, Moscow, Russia
| | | | - A N Belova
- Privolzhsky Research Medical University, Nizhny Novgorod, Russia
| | - O V Kolokolov
- Razumovsky Saratov State Medical University, Saratov, Russia
| | - L G Zaslavsky
- Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia
| | - N M Khasanova
- Northern State Medical University, Arkhangelsk, Russia
| | | | | |
Collapse
|
4
|
Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IY, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YV, Trushnikova TN, Khabirov FA, Chefranova JY, Shchur SG, Dudin VA, Pokhabov DV, Bolsun DD, Eremeeva AV, Linkova YN, Zinkina-Orikhan AV. [Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS]. Zh Nevrol Psikhiatr Im S S Korsakova 2023; 123:43-52. [PMID: 37560833 DOI: 10.17116/jnevro202312307243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/11/2023]
Abstract
OBJECTIVE To evaluate the efficacy and safety of the anti-CD20 monoclonal antibody divozilimab (DIV) used as an intravenous infusion at a dose of 500 mg for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) in comparison with the teriflunomide (TRF). The study of the efficacy and safety of the use of the drug DIV was carried out for 48 weeks of therapy. MATERIAL AND METHODS The multicenter, randomized, double-blind and double-masked phase III clinical trial (CT) BCD-132-4/MIRANTIBUS included 338 adult patients with RRMS distributed in a 1:1 ratio into two groups: DIV 500 mg and TRF 14 mg. After screening, subjects were included in the main CT period, which consisted of two cycles of therapy over 48 weeks. The primary end point was «Mean annualized relapse rate 48 weeks after the last patient is randomized in the study». RESULTS 321 subjects completed 48 weeks of therapy according to the study protocol. The analysis of the of efficacy data for the primary endpoint successively proved the hypothesis of superiority of the test drug DIV at a dose of 500 mg over the reference drug TRF. A rapid suppression of acute disease activity according to the brain MRI and clinical manifestations of the disease was shown after the first infusion of DIV in patients with RRMS. Thus, after 48 weeks of therapy in patients treated with DIV, there were no T1 gadolinium-enhancing lesions, while in the TRF group such lesions were observed in 20.7% (35/169) of subjects. Evaluation of the CUA per scan showed that the mean values for the estimated period were statistically significantly lower in the DIV drug group compared to the TRF group: the ratio of the adjusted per scan rates (DIV/TRF) was 0.125 [95% CI: 0.089; 0.177]. Over the 48 weeks of therapy, the proportion of subjects with relapses was 9.5% (n=16/169) in the DIV group and 19.5% (33/169) in the TRF group (p=0.0086). DIV has shown a favorable safety profile. Among the adverse reactions (AR), infusion reactions and deviations of laboratory data, such as a decrease in the number of leukocytes, neutrophils, and lymphocytes, were most often recorded. Identified AR were expected, had mild to moderate severity, and resolved without any negative consequences. CONCLUSION The results of the clinical study indicate the high efficacy and safety of DIV in comparison with TRF.
Collapse
Affiliation(s)
- A N Boyko
- Pirogov Russian National Research Medical University, Moscow, Russia
- Federal Center of Brain and Neurotechnologies of the Federal Medical Biological Agency, Moscow, Russia
| | | | | | | | - I V Greshnova
- Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Russia
| | - L G Zaslavsky
- Leningrad Regional Clinical Hospital, St. Petersburg, Russia
| | - S V Kotov
- Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia
| | - N A Malkova
- State Novosibirsk Regional Clinical Hospital, Novosibirsk, Russia
| | - G N Mishin
- Pyatigorsk City Clinical Hospital No. 2, Pyatigorsk, Russia
| | - E V Parshina
- Semashko Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod, Russia
| | | | - L N Prakhova
- N. Bechtereva Institute of the Human Brain, St. Petersburg, Russia
| | | | | | - N A Totolyan
- Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia
| | | | | | - F A Khabirov
- Republican Clinical Nerological Center, Kazan, Russia
| | - J Yu Chefranova
- Belgorod Regional Clinical Hospital of St. Joasaph, Belgogrod, Russia
| | - S G Shchur
- Municipal Filatov Clinical Hospital No. 15, Moscow, Russia
| | - V A Dudin
- Center for Cardiology and Neurology», Kirov, Russia
| | - D V Pokhabov
- Federal Siberian Scientific and Clinical Center, Krasnoyarsk, Russia
| | | | | | | | | |
Collapse
|
5
|
Boyko AN, Bakhtiyarova KZ, Dudin VA, Zaslavsky LG, Malkova NA, Parshina YV, Fedulov AS, Zinkina-Orikhan AV, Linkova YN, Ivanov RA, Chernovskaya TV. [The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova 2020; 119:100-109. [PMID: 31934995 DOI: 10.17116/jnevro201911910100] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
AIM To evaluate the efficacy and safety of BCD 054 180 μg and 240 μg administered once every 2 weeks for the treatment of remitting multiple sclerosis compared to placebo and low dose interferon beta-1a (LIB) 30 μg administered once weekly. Results of a 20 week blinded interim analysis from a double blind, comparative, randomised, placebo-controlled clinical study are included. MATERIAL AND METHODS This multinational, multicentre, double blind, comparative, placebo-controlled study enrolled 399 patients with the diagnosis of remitting multiple sclerosis: 114 patients in the sampeginterferon beta 1a and LIB groups each and 57 patients in the placebo group. To ensure the objectivity of data, the study protocol includes a blinded interim analysis to demonstrate the superiority of BCD 054 over placebo based on the number of combined unique active lesions (CUA) on MRI scans after 20 weeks of treatment. RESULTS AND CONCLUSION An integrated analysis of the efficacy, safety, pharmacokinetics, and pharmacodynamics was performed after 20 weeks of study. Mean CUA per scan was lower in the active treatment groups compared to placebo: 0,986±2,046, 0,619±1,055, 0,665±1,165, 1,673±2,376 (groups 1, 2, 3 and placebo group, respectively). The data for CUA per scan demonstrated the superiority of both BCD 054 180 μg and 240 μg over placebo. Patients receiving active treatment had fewer new and/or enlarging lesions after 20 weeks of treatment. The proportion of patients without new T2-weighted lesions was 74,3%, 86,7%, and 78,1% in groups 1, 2, and 3 compared to 64,9% in the placebo group. Manifestations of flu-like syndrome that is expected for interferon treatment were observed with the same incidence in all the active treatment groups. Its severity, duration or the need for symptomatic treatment did not appear to depend on the type of interferon used.
Collapse
Affiliation(s)
- A N Boyko
- Russian National Medical Research University named after N.I. Pirogov, Moscow, Russia; Federal Center for Cerebrovascular Pathology and Stroke, Moscow, Russia; 'Neuro-Clinic', Moscow, Russia
| | - K Z Bakhtiyarova
- State Budgetary Healthcare Institution 'Republican Clinical Hospital named after G.G. Kuvatov', Ufa, Republic of Bashkortostan, Russia
| | - V A Dudin
- Kirov Regional State Clinical Budgetary Healthcare Institution 'Cardiology and Neurology Centre', Kirov, Russia
| | - L G Zaslavsky
- State Budgetary Healthcare Institution 'Leningrad Regional Clinical Hospital', Saint Petersburg, Russia
| | - N A Malkova
- State Budgetary Healthcare Institution of Novosibirsk Region 'State Novosibirsk Regional Clinical Hospital', Novosibirsk, Russia
| | - Ye V Parshina
- State Budgetary Healthcare Institution of 'Nizhny Novgorod Region Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko', Nizhny Novgorod, Russia
| | - A S Fedulov
- State Institution 'Minsk Research and Development Centre of Surgery, Transplantology, and Haematology', Minsk, Republic Belarus
| | | | | | | | | |
Collapse
|